News

Working mum swapped a career in retail for a role in research into COVID-19.

A drug called Osimertinib has just been approved for routine use for people with early-stage EGFR-driven lung cancers in a landmark UK agreement. Dr Carles Escriu, a Consultant Medical Oncologist specialising in thoracic cancers at The Clatterbridge Cancer Centre NHS Foundation Trust, explains why this matters and how Osimertinib could benefit people with early-stage lung cancer linked to EGFR gene mutation.

Information about how people who have/had blood cancer, their relatives/carers and others with experience of blood cancer services can have their say on proposals aimed at further enhancing the care people receive at Aintree University Hospital and Clatterbridge Cancer Centre - Liverpool.

38-year-old Rob Gore’s diagnosis is very rare for a man of his age.

​When Debbie Roberts’ cancer treatment ended, it was just the start of her involvement in finding new ways to give hope to others with the disease. Debbie is living with ovarian cancer that is now in check and is part of a research trial designed to improve outcomes for other women with an advanced form of the disease.

Paula, who is being treated by The Clatterbridge Cancer Centre, has become one of the first people in England to benefit from a new 5-minute breast cancer treatment being rolled out across the NHS. Phesgo combines trastuzumab and pertuzumab into a single injection for HER2-positive breast cancers.

Edina Szilveszter had told friends she felt something “wasn’t right” before being diagnosed with a brain tumour.

Pioneering great-grandmother marks 200th treatment for breast cancer

Do you want to help to develop care at The Clatterbridge Cancer Centre Foundation Trust and ensure that our services are the best that they can be?

Retired care worker showed none of the typical signs of the disease.